COMPANY
R&D Experience
Novel Drug TPP (Target Product Profile and Analysis) and Clinical Translational Research
| Pharmaceutical company | Drug | Content |
|---|---|---|
|
STI571(Gleevec) | World’s First targeted Therapy/ BCR-ABL inhibitors |
|
|
PKI166 | Pre-Clinical Research on EGFR and HER2 Targeted Therapy |
|
Irresa | Pre-Clinical Research on EGFR and HER2 Targeted Therapy |
|
|
AEE788 | Development of EGFR/VEGFR dual inhibitors |
|
Bosentan & Macitentan | Repositioning of cardiovascular drug to brain cancer and metastatic brain tumor treatment drug |
|
Greenstatin | Advisory for Green Cross’s Development of new cardiovascular inhibitor |
|
|
MSLN-CAR-T | Joint research on MSLN-CAR-T cellular treatment drug with Green Cross |
|
Avastin | Pre-Clinical Research of VEGF Targeted Therapy |
|
|
DPP-4 inhibtor | Global Phase 3 and Phase 4 clinical TRIALS tests for diabetes drugs |
|
INVOSSA | Korea Local BLA approval and US clinical phase 1 and 2 clinical trials for osteoarthritis treatment drug |
|
NAD+ modulator | Korea Local Clinical trial for mitochondria anomaly disease treatment drug and License out to NeuroVive |
|
|
Utoma | Korea Local Clinical Trials and Approval for atopic dermatitis treatment drug |
|
|
YPL001 | Conducted phase 1 and 2 clinical trials for chronic obstructive lung disease natural drugs |
|
Sonazoid | Clinical Trials and US FDA NDA approval제q for liver cancer ultrasonic diagnosis drugs |
|
|
Sonazoid Vizamyl | Clinical Trials and US FDA approval for Alzheimer’s PET diagnostic drug (Flutemetamol) |
| etc | Involved in development of multiple anti-cancer drugs such as CXCR7 (3 molecules) targeted therapy and managed entire clinical translational trials | |